Trial of Cell-Based Therapy for High-Risk Lymphoma Leads to FDA Breakthrough ... 2024 — A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial cancer ...
Researchers at Cellectis leveraged gene editing to create a CAR T cell that acts in an IF/THEN system. Traditional methods to develop CAR T cells that use the patient’s cells introduce challenges ...
If left untreated, patients with these rare and aggressive forms of non-Hodgkin’s lymphoma typically ... bind to and kill the cancer cells. It is the second CAR-T to be recommended by the ...